Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This Rapid Response Report from the Canadian Agency for Drugs and Technologies in Health (CADTH) evaluated the efficacy, safety and cost-effectiveness of olopatadine, in c…
Author: NeLM - Ophthalmology
NETAG issues appraisal on Aflibercept (Eylea®) for AMD but defers recommendation
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has issued an appraisal report on aflibercept (Eylea®) for age-related macular degeneration (AMD) but deferred making a recommendation until…
NETAG issues updated recommendation on dexamethasone intravitreal implant (Ozurdex®) in uveitis
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has issued an updated recommendation supporting the use of Ozurdex® (dexamethasone intravitreal implant) for uveitis, only in accordance wit…
US FDA grants "orphan drug" status for verteporfin (Visudyne) for central serous chorioretinopathy
Source: GlobeNewswire, BioSpace
Area: News
The US Food and Drug Administration (FDA) has granted “orphan drug” status for verteporfin (Visudyne) for the potential treatment of chronic or recurrent central serous chorioretinopathy (CSC).
Moorfields Pharmaceuticals recalls selected batches of bevacizumab intravitreal injection 1.25mg/0.05ml following reports of suspected sterile endophthalmitis
Source: MHRA
Area: News
Moorfields Pharmaceuticals has issued a precautionary recall of selected lots (see list of batch numbers in document at link below) of bevacizumab intravitreal injection 1.25mg/0.05ml following a number of reports of suspected …
Horizon scanning: Positive phase III data for OMS302 intraoperative ocular drug
Source: BioSpace
Area: News
According to a Biospace report, positive phase III data have been reported for Omeros’ experimental ocular drug, OMS302. The drug is a combination of the anti-inflammatory agent ketorolac and the mydriatic agent phenylephr…
Seminar: Retinoblastoma
Source: Lancet
Area: News
Retinoblastoma is an aggressive eye cancer of infancy and childhood. In this Seminar, the authors draw attention to lessons learned about management and describe goals to ensure that all children with this condition receive t…
Horizon scanning: Aflibercept (EYLEA) approved for the treatment of wet age-related macular degeneration in Australia
Source: PharmaTimes
Area: News
PharmaTimes reports that the Australian regulatory authority (the Therapeutic Goods Administration – TGA) has approved EYLEA® (aflibercept) injection for the treatment of patients with neovascular (wet) age-related macu…
Review: Lichen Planus
Source: N Engl J Med
Area: News
Lichen planus is a mucocutaneous inflammatory disease of unknown origin. The skin and oral mucosa are the most frequently involved areas. Other mucous membranes (including the genitalia, oesophagus, and conjunctiva) and…
Verteporfin photodynamic therapy for neovascular age-related macular degeneration: UK cohort study
Source: National Institute for Health Research Health Technology Assessment programme.
Area: News
Infusion of verteporfin followed by infrared laser exposure is called (verteporfin photodynamic therapy -VPDT), and is used to treat neovascular age-rela…
Ocular safety of chronic use of sildenafil citrate in treatment of pulmonary arterial hypertension: data from phase III study and open label extension
Source: BMJ
Area: News
Selective phosphodiesterase type 5 inhibitors are capable of crossing the blood-retina barrier. Concerns have been raised about potential ocular side effects of sildenafil; the most common visual disturbance reported is a dose d…
Review: Managing retinal vein occlusion
Source: BMJ
Area: News
This review in the BMJ discusses the diagnosis and management of retinal vein occlusion and examines the evidence for the effectiveness of the newly licensed drugs. Questions addressed include:
. How and where do…
Ranibizumab for diabetic macular oedema: results from 2 RCTs (RISE and RIDE)
Source: Ophthalmology
Area: News
The efficacy and safety of intravitreal ranibizumab in diabetic macular oedema (DMO) has been evaluated in two parallel, methodologically identical, phase III, studies (RISE and RIDE).
The studies involved …
NHS Choices assessment of press reports that sight problems predicted to rise in UK
Source: NHS Choices
Area: News
NHS Choices has conducted an assessment of press reports, including one in the Daily Express that “the UK could face a ‘bindness epidemic’ caused by progressive eye conditions that is being grossly underestimated by the …
HORIZON: Open-label extension studies evaluating repeated intravitreal ranibizumab in neovascular AMD and macular oedema due to retinal vein occlusion
Source: Ophthalmology
Area: News
Two studies (HORIZON) published early online in Ophthalmology have reported outcomes of extended use ranibizumab for neovascular age-related macular degeneration, and macular oedema due to retinal vein occlusion, with…
Horizon scanning: FDA approves tafluprost (ZioptanT) preservative-free ophthalmic solution) for glaucoma or ocular hypertension
Source: PharmaLive
Area: News
According to a Pharmalive report, the US Food and Drug Administration (FDA) has approved tafluprost (ZioptanT) preservative-free ophthalmic solution) for reducing elevated intraocular pressure (IOP) in patients with open-…
NHS Choices ‘Behind the Headlines’ assessment of press reports that vitamin D ‘may stop AMD sight loss’
Source: NHS Choices
Area: News
The ‘Behind the Headlines’ service from NHS Choices has featured a quality assessment of press reports that “more vitamin D a day could keep glasses away” (reported by The Independent and others; 17th January 2012).
&…
NETAG issues appraisal but defers recommendation on Ozurdex® (dexamethasone intravitreal implant) for uveitis
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has appraisal report on the use of Ozurdex® (dexamethasone intravitreal implant) for uveitis. The Group opted to defer its recommendation pe…
Avoiding unnecessary referral for glaucoma: use of a repeat measurement scheme
Source: NHS Networks
Area: News
Bexley Clinical Commissioning Cabinet/Business Support Unit has announced that a scheme in which the referring optometrist conducts a repeated test before deciding whether or not to refer a patient with glaucoma has res…
SMC unable to recommend dexamethasone (Ozurdex ®) intravitreal implant due to absence of submission
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) is unable to recommend the use of dexamethasone (Ozurdex ®) 0.7mg intravitreal implant within NHS Scotland for the treatmen…